To include your compound in the COVID-19 Resource Center, submit it here.

Alexo reports Phase I data for its CD47 inhibitor

Alexo Therapeutics Ltd. (Dublin, Ireland) reported data from 17 patients with advanced solid tumors and lymphoma in

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE